Table 2 Demographics and clinical variables
Total n = 17 | |
|---|---|
Age [years] | 60.5 (± 9.9) |
Gender [n] | |
Male | 15 (88.2%) |
Female | 2 (11.8%) |
BMI [kg/m2] | 26.7 (19.8–43.9) |
– Overweight (BMI 25–30 kg/m2) | 9 (52.9%) |
– Obese (BMI ≥ 30 kg/m2) | 3 (17.6%) |
Jaundice [n] | 3 (17.6%) |
Pruritus [n] | 5 (29.4%) |
Length of ICU stay [weeks] | 10 (2–28) |
ARDS [n] | 17 (100%) |
ECMO support [n] | 6 (35.3%) |
Ketamine [n]* | 7 (41.2%) |
Preexisting liver disease [n] | 3 (17.6%) |
– NASH | 1 |
– Isolated GGT elevation | 1 |
– History of hepatitis A and hepatitis B infection | 1 |
Abnormal liver function tests [n] | 17 (100%) |
Laboratory markers (at time of imaging) | |
– Aspartate aminotransferase (AST) | 143.7 U/l (± 117.0) [x2.9 ULN (± 2.3)] |
– Alanine aminotransferase (ALT) | 158.1 U/l (± 118.5) [x3.2 ULN (± 2.4)] |
– Gamma glutamyltransferase (GGT) | 1365.1 U/l (± 1579.8) [x10.3 ULN (± 8.6)] |
– Alkaline phosphatase (ALP) | 620.2 U/l (± 516.3) [x4.8 ULN (± 4.0)] |
– Bilirubin (total) | 97.4 µmol/l (± 134.5) [x4.6 ULN (± 6.4)] |
Laboratory markers (peak) | |
– Aspartate aminotransferase (AST) | 334.1 U/l (± 419.9) [x6.7 ULN (± 8.4)] |
– Alanine aminotransferase (ALT) | 367.1 U/l (± 412.4) [x7.3 ULN (± 8.2)] |
– Gamma glutamyltransferase (GGT) | 1908.8 U/l (± 1327.6) [x31.8 ULN (± 22.1)] |
– Alkaline phosphatase (ALP) | 1181.5 U/l (± 1044.4) [x9.1 ULN (± 8.0)] |
– Bilirubin (total) | 140.5 U/l (± 200.2) [x6.7 ULN (± 9.5)] |